Research Publications

Prevalence of Hypercortisolism in Difficult-to-Control Type 2 Diabetes.

Buse JB, Kahn SE, Aroda VR, Auchus RJ, Bailey T, Bancos I, Busch RS, Christofides EA, DeFronzo RA, Eilerman B, Findling JW, Fonseca V, Hamidi O, Handelsman Y, Miller HJ, Ownby JG, Parker JC, Philis-Tsimikas A, Pratley R, Rosenstock J, Shanik MH, Sloan LL, Umpierrez G, Tudor IC, Schlafly TK, Einhorn D, CATALYST Investigators*

Inadequately Controlled Type 2 Diabetes and Hypercortisolism: Improved Glycemia With Mifepristone Treatment.

DeFronzo RA, Fonseca V, Aroda VR, Auchus RJ, Bailey T, Bancos I, Busch RS, Buse JB, Christofides EA, Eilerman B, Findling JW, Handelsman Y, Kahn SE, Miller HJ, Ownby JG, Parker JC, Philis-Tsimikas A, Pratley R, Rosenstock J, Shanik MH, Sloan LA, Umpierrez G, Shambharkar S, Tudor IC, Schlafly TK, Einhorn D, CATALYST Investigators*

Clinical Use of Once-Weekly Insulin Icodec: Translating Clinical Trial Data into Practical Guidance for Diabetes Management.

Philis-Tsimikas A, Aberle J, Bajaj H, Lingvay I, Mu Y, Shaikh S, Vianna A, Watada H, Del Prato S

Insights on Hospitalisations from the Phase 3a ONWARDS 1-6 Trials of Once-Weekly Insulin Icodec.

Philis-Tsimikas A, Krogsdahl Bache J, Fu A, Kellerer M, Salvesen-Sykes K, Bain SC

Factors Associated with Progression to Type 2 Diabetes among Women with Gestational Diabetes.

Liu J, Yang C, Liu B, Kim R, Philis-Tsimikas A, Isasi C, Wolfe D, Levy C, Moon JY, Li L

Quantifying Environmental Waste From Diabetes Devices in the U.S.

Tian T, Ho CN, Ayers AT, Aaron RE, Klonoff DC, Ahn DT, Kerr D, Peters AL, Philis-Tsimikas A, Shah VN, Herndon EG, Yang Y, Li C, Wang J

Copenhagen Declaration: a transformative vision for global diabetes.

Narayan KMV, Global Diabetes Forum (2024)

Once‑weekly IcoSema versus once‑weekly insulin icodec in type 2 diabetes management (COMBINE 1): an open‑label, multicentre, treat‑to‑target, randomised, phase 3a trial.

Mathieu C, Giorgino F, Kim SG, Larsen JH, Philis-Tsimikas A, Ramachandran A, Pagliaro Rocha TM, Shankarappa VB, Terauchi Y, Ji L

Once-weekly insulin efsitora alfa versus once-daily insulin degludec in adults with type 2 diabetes currently treated with basal insulin (QWINT-3): a phase 3, randomised, non-inferiority trial.

Philis-Tsimikas A, Bergenstal RM, Bailey TS, Jinnouchi H, Thrasher JR, Ilag L, Mitra J, Syring K, Threlkeld RJ

Oral Semaglutide and Cardiovascular Outcomes in High-Risk Type 2 Diabetes.

McGuire DK, Marx N, Mulvagh SL, Deanfield JE, Inzucchi SE, Pop-Busui R, Mann JFE, Emerson SS, Poulter NR, Engelmann MDM, Ripa MS, Hovingh GK, Brown-Frandsen K, Bain SC, Cavender MA, Gislum M, David JP, Buse JB, SOUL Study Group